Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib + Gemcitabine/Cisplatin in Cholangiocarcinoma
NCT02128282Phase 2Completed
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Jun 2014
- Primary completion
- Nov 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of silmitasertib in cholangiocarcinoma (CCA) (4 arms), sponsored by Senhwa Biosciences, Inc. Primary endpoints: Maximum Tolerated Dose, Progression-Free Survival up to 52 weeks and 1 more. Started Jun 2014; status: completed.
02
Drugs
silmitasertib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02128282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128282.